UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January, 2025
Commission File Number: 001-42128
Telix Pharmaceuticals Limited
(Translation of registrant’s name into English)
55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On January 13, 2025, Telix Pharmaceuticals Limited (the "Company") filed with the Australian Securities Exchange (the "ASX") an announcement (the “Announcement”) captioned “TLX to Acquire Next-Gen Therapeutics and Biologics Platform,” a copy of which is attached to this Form 6-K as Exhibit 99.1.
Attached as Exhibit 99.2 is a presentation the Company filed with the ASX on January 13, 2025 in connection with the Announcement.
| Announcement - January 13, 2025. |
| Presentation - January 13, 2025. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | |
| | Telix Pharmaceuticals Limited |
| | | |
| Date: January 13, 2025 | By: | /s/ Genevieve Ryan |
| | | Name: Genevieve Ryan |
| | | Title: Company Secretary |
